Tempus AI, Inc. — Form 8-K
Filed November 2, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 62/100
What the filing says
Tempus AI reported Q3 2026 revenue of $411.5M (23% YoY growth), with oncology volume up 32% and Data Applications revenue up 33%. The company raised full-year 2026 revenue guidance to $1.60–$1.605B (~25% growth) and expects ~$65M Adjusted EBITDA. Major developments: (1) Strategic collaboration with Merck and Moderna for neoantigen therapy commercialization; (2) BMS data licensing deal worth $137.5M over 5 years for oncology data plus $55M for Alzheimer's/dementia data; (3) Personalis acquisition regulatory clearance granted (shareholder vote Nov 30, 2026); (4) Two FDA 510(k) clearances for cardiology products. Cash position: $854.4M.
Why this rating
Strong Q3 revenue growth (23% YoY) and raised FY guidance represent solid operational momentum. BMS partnership ($192.5M total) and Merck/Moderna deal add meaningful diversification and validation. Personalis acquisition (clearance granted) is transformational for scale, though final approval pending. At $11B market cap, $411.5M quarterly revenue is ~15% run-rate—meaningful but not revolutionary. Guidance raise and path to positive Adjusted EBITDA are encouraging signals, offsetting still-negative GAAP net loss.
See more from November 2, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.